Parenteral Manual

Folic acid

Disclaimer: Official controlled document is the CHEO online copy. It is the responsibility of user to ensure that any paper copy version is the same as the online version before use.

Alternate Name(s): 
Hematopoietic vitamin, anemia therapy
Original Date: 
August 2005
Revised Date: 
December 2019
  • Folate deficiency due to inadequate intake or absorption; or increased utilization or excretion
  • Treatment of megoblastic and macrocytic anemias due to folate deficiency
Reconstitution and Stability: 
  • Store at room temperature
  • Available as 5 mg/mL solution
  • Protect from light and heat
  • Solutions are clear yellow to orange yellow in colour
  • Vial stable for 3 days at room temperature once punctured

- Solutions Compatible: dextrose solutions up to D20W, NS

- Additives/Above Cassette Compatible: no information

- Y-site Compatible: TPN (amino acids/dextrose), KCl

- Incompatible: oxidizing and reducing agents, heavy metal ions, morphine


(For approved routes of administration by nursing personnel, refer to Policy for the Administration of Intravenous Medications.)

IM YES, deep into muscle
IV Direct

Usual dilution: 5 mg/mL
Infusion rate: 5 mg/minute

IV Intermittent Infusion YES
Usual dilution: 0.1 mg/mL   
Infusion time: 20 minutes
IV Continuous Infusion YES, in TPN

(For neonatal dosages, refer to Neonatal IV Drug Manual.)

  • Give orally, except in severe intestinal malabsorption or when oral administration is not feasible        

Folic Acid deficiency:


  • 15 mcg/kg/dose daily or 50 mcg/day SC/IM/IV

Children 1-10 years:   

  • Initial: 1 mg/day SC/IM/IV
  • Maintenance: 0.1-0.4 mg/day

Children > 11 and Adults:

  • Initial: 1 mg/day SC/IM/IV
  • Maintenance: 0.5 mg/day
Potential hazards of parenteral administration: 
  • Allergic reactions (rare):  erythema, rash, itching, general malaise, bronchospasm
  • Will not prevent neurologic abnormalities due to vitamin B12 deficiency, although the hematological effects may be masked.
  • May mask the diagnosis of pernicious anemia
  • Contraindicated in pernicious, aplastic and normocytic anemias
  • IV and oral doses are equivalent on a mg per mg basis
  • May decrease serum phenytoin concentrations
  • Injectable may be given orally


The information contained on this website is provided for informational purposes only, as a guide to assist physicians, nurses and other healthcare providers in deciding on the appropriate care required for a particular patient. At all times, physicians, nurses and other healthcare providers must exercise their independent clinical judgment, based on their knowledge, training and experience, taking into account the specific facts and circumstances of each patient, when deciding on the appropriate course of investigation and/or treatment to recommend in a particular clinical situation.

CHEO has made every effort to ensure that the information contained on this website is as current and accurate as possible. However, changes can occur due to ongoing research and the constant influx of new information. Where possible, hospitals and healthcare practitioners should verify the information before acting on it.

Reliance on any information in this website is at the user's own risk. CHEO is not responsible or liable for any harm, loss or other consequences from the use or misuse of the information on this website.